Medical Technologies Firm to Create 100+ Jobs at New Wisconsin Facility
01/25/2012
SHINE serves the medical tracer industry sector by providing medical ingredients used to detect/treat heart disease and cancer in nearly 100,000 patients each day.
"As a company that grew in partnership with research conducted at UW-Madison and the Morgridge Institute for Research, one of our primary goals was to grow this business in Wisconsin and leverage its talented workforce," said SHINE's Founder/CEO Greg Piefer, Ph.D.
The company's proposed facility, to be located in the STH 11 Business Park, will have the capacity to produce enough moly-99 to supply about half of the U.S. nuclear medical isotope needs. (Moly-99 is a medical isotope to help detect heart disease and determe stages of cancer progression.) Historically, the majority of the moly-99 used in the U.S. has been produced in Canada or from other locations across the globe.
Pending formal approval, SHINE's project will be supported by a combination of resources, including a Janesville Tax Increment Financing (TIF) package and assistance from the Wisconsin Economic Development Corporation. The facility marks the second medical technologies announcement in Rock County within the last eight months.
Most Read
-
-
A Turnkey Approach to Manufacturing Location Decisions
Q2 2021
-
Life Sciences Fueling Construction Demand
Q2 2021
-
2020 Top States for Doing Business Showcase Their Pro-Business Environments
Q3 2020
-
What’s Driving Record Industrial Real Estate Demand
Q1 2021
-
35th Annual Corporate Survey: Effects of Global Pandemic Reflected in Executives’ Site and Facility Plans
Q1 2021
-
In Focus: The Effects of the Pandemic on Industrial Design
Q2 2021